Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002902 · ClinicalTrials.gov registry record · Phase 1
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002902: Completed Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT00002902 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002902, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
Interventions
- DRUG irinotecan hydrochloride
- DRUG raltitrexed
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-04 |
| Phase | Phase 1 |
What the finished NCT00002902 record still lists
NCT00002902 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00002902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002902 about?
NCT00002902 is a clinical study titled "Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tum...
What is the current status of trial NCT00002902?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-04.
What interventions are being tested in trial NCT00002902?
The interventions under investigation include: irinotecan hydrochloride (DRUG), raltitrexed (DRUG).
Who is sponsoring clinical trial NCT00002902?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia